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We have studied the interaction of the reversible acetylcholine esterase inhibitor (-)physostigmine (D-eserine)
with the nicotinic acetylcholine receptor (nAChR) from Torpedo marmorata electric tissue by means of ligand-
induced ion flux into nAChR-rich membrane vesicles and of equilibrium binding. We find that (—)physostigmine
induces cation flux (and also binds to the receptor) even in the presence of saturating concentrations of antagonists
of acetylcholine, such as D-tubocurarine, a-bungarotoxin or antibody WF6, The direct action on the acetylcholine
receptor is not affected by removal of the methylcarbamate function from the drug and thus is not due to
carbamylation of the receptor. Antibodies FKl and benzoquinonium antagonize channel activation (and binding)
of eserine, suggesting that the eserine binding site(s) is separate from, but adjacent to, the acetylcholine binding
site at the receptor. In addition to the channel activating site(s) with an affinity of binding in the 50 nM range,
there exists a further class of low-affinity (K^ ~ mM) sites from which eserine acts as a direct blocker of the
acetylcholine-activatcd channel. Our results suggest the existence of a second pathway of activation of the nAChR
channel.
The nicotinic acetylcholine receptor (nAChR) from
muscle, brain and electric tissue is a ligand-gated cation chan-
nel [1—3], Binding of acetylcholine, or its agonists, induces
transient openings of the channel. Antagonists compete with
acetylcholine and its agonists in binding to the receptor
thereby blocking the channel-activating action of agonists.
Other ligands (non-competitive blockers, direct channel
blockers) modulate the agonist-activated channel by binding
to separate sites [1, 3],
Physostigmine (eserine) is a slowly reversible inhibitor of
acetylcholine esterase which acts by carbamylation of the ac-
tive serine residue within the 'esteratic site' of the enzyme [4],
The carbamylated enzyme intermediate undergoes hydrolysis
more slowly than the acetylated intermediate (in the case
of acetylcholine hydrolysis), resulting in a slowly reversible
inhibition of the enzyme, Eserine exerts both peripheral and
central cholinomimetic actions. In contrast to the action of
other anticholinesterases such as the organophosphates, how-
ever, eserine and other carbamates have quite diverse actions
on the pre- and pwstsynaptic region of neuromuscular junc-
tions [5 — 7] suggesting that carbamylation of the enzyme
might not bie their only mode of action. Recently, the labora-
tory of Albuquerque has provided electrophysiological evi-
dence in favour of a direct action of carbamates at the nAChR
[8-12], (-)Physostigmine (eserine), at concentrations below
1 |iM, induced single channel currents with amplitudes and
open time characteristics typical for the nAChR channel
[8 — 13], This concentration is 5—10-fold below the IC50 of
acetylcholine esterase inhibition, suggesting that the direct
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action on the receptor might at least equal in importance
the action on the enzyme. At higher concentrations, eserine
exhibits noncompetitive antagonism with respiect to chol-
inergic agonists, accompanied by rapid opening and closing
events (flickering) of the activated channels [8 — 10, 14].
Vesicular membrane fragments from Torpedo electric tis-
sue permit the direct measurement of both ligand binding to
the nAChR and ligand-induced ion flux through the nAChR-
integral cation channel. To remain within the time range of
excitatory events at the neuromuscular junction, ion flux is
best studied by time-resolved fluorimetry employing rapid-
mixing devices [15—18], For this purpose, we prepared su-
crose-gradient-purified membrane vesicles from T. marmorata
electric tissue [19], loaded them with 1,3,6,8-pyrene tetra-
sulfonate [20], and monitored the quenching of fluorescence
induced by influx of Cs* [21] after rapid mixing, in a stopped-
flow apparatus, of dye-loaded membrane vesicles with a buffer
containing the heavy metal quencher and eserine. In addition
to thereby establishing an agonistic action of eserine at Tor-
pedo nAChR, our studies produced several novel findings. The
agonistic action of eserine could not be blocked by established
cholinergic antagonists, including D-tubocurarine, a-
bungarotoxin and the competitive antibody WF6 [22], On
the contrary, under these conditions of blocked acetylcholine
binding sites, eserine uninhibitedly activated the nAChR chan-
nel. Searching for compounds that antagonize the channel-
activating action of eserine, we established two monoclonal
antibodies and a low-molecular-mass compound that com-
peted with eserine in binding to Torpedo membrane fragments.
Taken together, eserine exerts its agonistic effects ftxjm sites
at the nAChR independent of those for the natural transmitter,
and thus may mimick properties of an (as yet unidentified)
endogenous ligand of the nAChR,
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EXPERIMENTAL PROCEDURES
Preparation of membrane vesicles
mAChR-rich membrane vesicles were prepared from Tor-
pedo marmorata electric tissue according to [23] with the minor
modifications described in [19]. Following sucrose gradient
fractionation, the fraction with the highest concentration of
nAChR was pooled, diluted with a 10-fold excess of ice-cold
distilled water and centrifuged for 30 min at 18000 rpm in an
SS 34 rotor. The pellet was resuspwnded in 300 mM NaCl,
10 mM Hepes pH 7.0 and stored at — 80 C. The receptor
concentration of the suspension was generally 17 — 20 nM in
terms of acetylcholine binding sites at a protein concentration
of 10-14 mg/ml.
Ion flux studies
Ion flux studies were performed according to [16] with
the following modifications: 1,3,6,8-pyrene tetrasulfonate was
used as fluorescent dye, and Cs * instead of Tl * was used as
heavy metal quencher [21]. Loading of the membrane vesicles
with dye was achieved by three cycles of freezing (in liquid
nitrogen) and thawing (in ice water). Excess dye was removed
by passage through a column of Sephadex G-25 (coarse) equi-
librated with Na/Hepes buffer (300 mM NaCl, 10 mM Hepes
pH 7.0), the elution time being approximately 15 min. The
eluate was then made 50 nM in the esterase blocker Tetram.
The receptor concentration of the vesicle suspension after
passage through the column was of the order of 1 \iM
acetylcholine binding sites.
The vesicle suspension was rapidly mixed in a HighTech
SF-51MX stopped-flow fluorimeter with an equal volume of
Cs/Hepes buffer (300 mM CsCl, 10 mM Hepes pH 7.0) with
or without activating ligand. Excitation of fluorescence was
by a 240-W xenon/halogen lamp with the light being passed
through a Schott UG 11 ultraviolet broad-band filter com-
bined with a UG 11 RB filter. The emitted light was passed
through a Schott KV 399 filter before reaching the photo-
multiplier. After A/D conversion, the signals were collected in
a personal computer equipped with a Sorcus modular IV card.
The reported kinetic traces were each averaged from at least
five independent experiments.
Ion fiux experiments were performed at 19.6 C within
90 min after loading of the vesicles. Preincubation with small
ligands (D-tubocurarine, dibucaine, acetylcholine) was per-
formed with dye-loaded vesicles for 30 min; preincubation
with high-molecular-mass ligands (neurotoxins, antibodies)
was performed overnight prior to loading the vesicles with
fluorescent dye. All experiments were performed in the pres-
ence of the esterase blocker Tetram. Tetram itself did not show
any activity towards the nAChR.
Binding experiments
Binding of tritiated acetylcholine or eserine to membrane-
bound nAChR was performed with crude Torpedo membrane
preparations [24]. The stock suspension of membranes was
diluted into 100 mM NaCl, 4 mM CaCb, 2 mM MgCl2,
10 mM Pipes pH 6.8, supplemented with 0.5 mg/ml bovine
serum albumin, repeatedly shock frozen in liquid nitrogen (to
open endogenous presynaptic vesicles), and finally sup-
plemented with 0.125 mM Tetram. Aliquots of 400 nl were
transfered into Eppendorf reaction vials and, after addition
of the appropriate ligands, the total reaction volume was
adjusted to 500 \i\ with bufier. After incubation for 30 min at
room temperature (in the presence of eserine in the dark), the
vials were centrifuged under refrigeration (4 C) in an SS34
rotor at 20000 rpm for 60 min. The free concentration of
radioactive ligand was determined from 100-(il aliquots of
the supernatant. After careful removal of the supernatant by
suction and absorption by the tip of a paper towel, the bottom
of the reaction vial was clipped oil, and the radioactivity in
the pellet (bound ligand) was determined. Nonspecific binding
increased linearily with the concentration of radioactive ligand
employed. It was determined by linear regression and sub-
stracted from total radioactivity bound.
Binding of antibody FKl to membrane-bound nAChR
was studied by ELISA [25, 26] employing either crude or
highly purified membrane preparations. For quantitative
analysis, the mon(x;lonal antibody was purified to apparent
homogeneity [22], the total concentration of immobilized
nAChR was determined in control wells by binding of a-
['H]bungarotoxin, the enzyme reactions were performed
under strictly controlled conditions, and all absorbance deter-
minations were performed within the linear range of the
spectrophotometer (Kuhlmann, J. and Maelicke, A., unpub-
lished results). Assuming 1:1 stoichiometry between antibody
and nAChR [22], the saturation level of absorbance is then
correlated with the concentration of immobilized nAChR per
well, and the ELISA curves can be analysed in terms of binding
equilibria. With the concentration of antibody and its affinity
of binding to the nAChR known, competition of eserine and
antibody for receptor binding can be studied. From the con-
centration of half-maximal competition, an apparent K, value
can then be calculated.
RESULTS
Eserine can activate the Torpedo nAChR channel even
in the presence of cholinergic antagonists
Fig. 1 summarizes the results of Cs* influx studies em-
ploying fiuorescent dye-loaded nAChR-rich Torpedo mem-
brane vesicles and eserine. As shown in Fig. 1 A, eserine-in-
duced quenching of fiuorescence exhibited similar properties
as previously observed by the same assay for acetylcholine
and its agonists [16-18, 22]. By inference, the initial rapid
decrease in fiuorescence is induced by the opening of eserine-
gated nAChR channels, with the slow phase of approach to
leakage flux levels representing desensitization of the same
channels [15-18]. As a control, the dye-loaded vesicles were
disrupted by the addition of organic solvent, e.g. 2% di-
methylsulfoxide, so that the total amount of vesicle-enclosed
dye was exposed to the heavy metal quencher. The amplitude
of fiuorescence quenching resulting from this treatment was
several times larger than the maximal amplitude of eserine-
induced quenching, showing that the latter was not limited
by exhaustion of free dye. The concentration dependence of
fiuorescence quenching could therefore be used to construct
a dose/response relationship resulting in an eserine concen-
tration required for half-maximal response of 300 — 500 |iM.
This concentration is approximately one order of magnitude
higher than that determined for acetylcholine [1, 3, 18].
The other panels of Fig. 1 demonstrate that eserine can
activate the Torpedo nAChR channel even in the presence of
antagonists of acetylcholine but not in the presence of the
noncompetitive inhibitor dibucaine. Fig. 1B contains the
traces of six different experiments, the first four of which
representing only leakage infiux of Cs* into the vesicles. The
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Fig. 1. Eserine-stimulated Cs* influx into membrane vesicles Jrom T. marmorata electric organ in the absence and presence of antagonists of
acetylchotine. (A) Concentration dependence of Cs* influx stimulated by eserine. Membrane vesicles (concentration of acetylcholine binding
sites approx. 1 (iM), loaded with 1,3,6,8-pyrenc tetrasulfonate and suspended in Na/Hepes buffer were rapidly mixed with Cs/Hepes buffer in
the absence (trace 1) and presence (traces 2, 3, 4) of (-)-physostigminc (D-eserine). The change in fluorescence was recorded as a function of
time. Trace 1 represents uninduced 'leakage' flux, i.e. the spontaneous equilibration of Cs* between extra vesicular and intravesicular space
m the absence of channel-activating ligands. Traces 2, 3 and 4 were obtained when Cs/Hepes buffer was supplemented with eserine to a final
concentration (after mixing) of 115 (lM, 920 jiM and 1.84 mM, respectively. Each trace represents the average of five experiments. From a
secondary plot of the quenching amplitudes versus the concentration of eserine applied, a half-maximal concentration for channel activation
of 350-400 MM was obtained. (B) D-Tubocurarine and decamethonium do not antagonize eserine-stimulated Cs* influx. Under similar
experimental conditions as described above, dye-loaded vesicles were incubated for 15min with 200 nM decamethonium (trace 2) or
tubocurarine (trace 3) or benzoquinonium (trace 4) followed by rapid mixing with an equal volume of Cs/Hepes buffer supplemented with
20 nM acetylcholine. The observed fluorescence decay curve was indistinguishable from leakage flux (trace 1) suggesting that the concentration
of inhibitor fully sufficed to block all cholinergic sites available. In contrast, when dye-loaded vesicles, preincubated with 200 nM deca-
methonium, were rapidly mixed with Cs/Hepes buffer supplemented with 200 nM eserine rather than acetylcholine, almost the same level of
channel activation (trace 5) as in the absence of decamethonium (trace 6) was observed. A similar kinetic as trace 5 was observed when the
vesicles were preincubated with D-tubocurarine. (C) Antibody WF6 does not antagonize eserine-stimulated Cs* influx. Traces 1 and 2,
membrane vesicles were pretreated overnight at 4 C with antibody WF6 ( * 50-fold excess over acetylcholine binding sites), loaded with
1,3,6,8-pyrene tetrasulfonate and then rapidly mixed with an equal volume of 40 nM acetylcholine in Cs/Hepes buffer. Only leakage flux was
observed. Trace 3, same experimental conditions as above expect that acetylcholine was replaced by 400 nM eserine. (D) The local anaesthetic
dibucaine inhibits eserine-stimulated Cs' influx. Trace 1, dye-loaded vesicles were rapidly mixed with Cs/Hepes buffer in the absence of
activating ligands (leakage flux). Trace 3, dye-loaded vesicles were rapidly mixed with Cs/Hcpes buffer containing 200 nM eserine. Trace 2,
dye-loaded vesicles were preincubated for 30 min with 200 nM dibucaine followed by rapid mixing with Cs/Hepes buffer containing 200 nM
eserine
(trace 1), and also in the presence of 20 ^M acetylcholine when
the vesicles were preincubated (prior to rapid mixing with
acetylcholine in Cs/Hepes buffer) with either 200 jiM deca-
methonium (trace 2) or 200 |iM D-tubocurarine (trace 3) or
200 nM benzoquinonium (trace 4). Trace 5 was observed when
dye-loaded vesicles pretreated with 200 nM decamethonium
(or 200 nM D-tubocurarine) were rapidly mixed with Cs/
Hepes buffer containing 200 \iM eserine instead of acetyl-
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choline. Clearly, the employed concentrations of decametho-
nium and D-tubocurarine sufficed to inhibit activation of the
receptor channel by acetylcholine while activation by eserine
uninhibitedly proceeded to a similar, if not identical, level as
in the absence of these cholinergic antagonists (trace 6). Hence,
since the afiinity of eserine binding to the receptor is much
below that of acetylcholine (see below), eserine appears to
activate the observed ion flux from other than the acetyl-
choline sites.
Similarly (Fig. 1C), preincubation of dye-loaded vesicles
with the acetylcholine-competitive antibody WF6 (22, 25]
blocked channel activation by acetylcholine but not by eserine.
The same was observed for antibody WF5 and the neurotoxin
a-bungarotoxin (not shown here). In contrast, the local anaes-
thetic dibucaine, an established open channel blocker of
acetylcholine activation [1, 3], also blocked channel activation
by eserine (Fig. 1 D) suggesting that acetylcholine and eserine
indeed act on the same channel, albeit from independent bind-
ing sites at the receptor.
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The carbamate structure is not required
for nAChR channel activation by eserine
Physostigmine, at neutral pH, is a positively charged tri-
cyclic amino compound with a methylcarbamate side chain.
Binding to acetylcholine esterase is assumed to occur via the
enzyme's 'anionic site' which places the carbamate group in
apposition to the 'esteratic site' of acetylcholine esterase [4].
To test whether carbamoylation of the receptor is associ-
ated with the channel-activating property of eserine, we hydro-
lysed away the A^-methylcarbamate group (the truncated
eserin acts as reversible competitive inhibitor rather than as
nearly irreversible inhibitor of acetylcholine esterase) and
performed ion flux studies as described above. Truncated
eserine exhibited the same channel-activating potency as
eserine, suggesting that the carbamate function is neither re-
quired for binding to the receptor, nor for channel activation.
This agrees with the inability of previous studies to identify
active serine residue(s) at the nAChR (by means of active-site
titration with [^HJdiisopropylfluorophosphate, [27, 28]).
For the same reason, the phosphorothiolate Tetram does
not activate or interfere with nAChR channel activation by
cholinergic agonists or by eserine. Tetram was hetice used as
an anticholinesterase in most of our experiments (a) to exclude
enzymatic hydrolysis of acetylcholine esterase substrates, and
(b) to reduce, if possible, the interaction of eserine with the
remaining traces of acetylcholine esterase in our preparation.
Antibody FKI and benzoquinonium antagonize
channel activation by eserine
We screened an available library of monoclonal antibodies
raised against nAChRs from different species for members
inhibiting eserine-induced ion flux into dye-loaded vesciles.
None of our antibodies raised against Torpedo nAChR [22,
25, 29] displayed such properties, but two others were found
that did. Antibody FKI (Fels, G., Kuhlmann, J. and
Maelicke, A., unpublished) was raised against hindleg muscle
cell membranes from newborn rats [30]; antibody PKl was
raised against a synthetic peptide conjugated to bovine serum
albumin [31]. As shown for FKI in Fig. 2A, preincubation
with saturating concentrations of the antibody completely
inhibited Cs^ influx into Torpedo membrane vesicles, estab-





Fig. 2. Eserine-stimulated Cs* influx into T. marmorata membrane
vesicles in the presence and absence of antibody FKI. (A) Antibody FK1
antagonizes eserine-stimulated Cs* influx. Traces 1 and 2, membrane
vesicles were pretreated overnight at 4"C with antibody FKI, loaded
with dye and rapidly mixed with equal volumes of 200 |iM eserine or
400 nM eserine in Cs/Hepes buffer. Both experiments yielded similar
traces suggesting that the concentration of FKI employed was close
to saturation. (The remaining small component of rapid fluorescence
quenching may be due to insufficient time of preincubation and/or
relatively low affinity of binding of antibody FKI.) Traces 3 and 4,
same experimental conditions as above except that the membrane
vesicles were not pretreated with antibody FKI. (B) Benzoquinonium
antagonizes eserine-stimulated Cs* influx. Dye-loaded membrane
vesicles were pre-treated for 15min with 100 nM benzoquinonium
followed by rapid mixing with an equal volume of Cs/Hepes buffer
supplemented with (trace 2) or without (trace 1) 200 nM eserine. Trace
3, dye-loaded membrane vesicles were not treated with benzo-
quinonium prior to rapid mixing with 200 nM eserine in Cs/Hepes
buffer
eserine. This finding is further supported by the binding stud-
ies reported below.
From an extensive screening program to identify low-mo-
lecular-mass antagonists of eserine, we found that the cho-
linergic antagonist benzoquinonium [32] inhibits the ion-flux-
inducing activity of both acetylcholine and eserine (Fig. 2B).
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This result may be of particular interest with respect to the
location of the eserine site(s) at the receptor. As no evidence
for other than acetylcholine-competitive benzoquinonium
binding sites at the nAChR exists [32], it is likely therefore
that eserine and acetylcholine bind to neighboring sites at the
receptor's a-subunit (with the binding site of benzoquinonium
overlapping with both sites).
Binding of eserine to Torpedo membrane fragments
Direct binding of [^H]eserine to membrane-bound nAChR
is difficult to assess because, even under equilibrium con-
ditions, the binding affinity remains low. The high concen-
trations of membrane-bound receptor therefore required for
binding studies [28], even if available, obscures the proper
separation of solute and particulate phase required by the
usual binding assays [24, 33, 34]. Therefore forced to working
at receptor concentrations below 1 nM (Fig. 3 A), we esti-
mated for eserine a ATj value of the order of 50-100 nM.
Thus, persistent occupation of nAChR by eserine increases
the affinity of eserine binding by only one order of magnitude,
while desensitization of the receptor by acetylcholine is ac-
companied by an increase in binding affinity for acetylcholine
of approximately three orders of magnitude [24, 34, 35].
Fig. 3 B displays the results of competition binding studies
with eserine and [•'H]acetylcholine. Only very weak inhibition
of [^H]acetylcholine binding was observed, resulting in a K,
value for eserine in the millimolar range. Obviously, the
acetylcholine-comjjetitive eserine binding site(s) differ in affin-
ity and probably also in location from those responsible for
the eserine-induced ion flux. They rather appear to represent
the sites of noncomf)etitive antagonism (direct channel block-
ade) previously identified by electrophysiological experiments
[8-13].
As a further approach to determine the affinity of binding
of eserine to the nAChR, its competition with antibody FKl
for receptor binding was studied (Schrattenholz, A. and
Maelicke, A., unpublished). Calculations based on the concen-
tration of eserine required for 50% reduction of FKl binding
to Torpedo nAChR yielded /ij values of the order of 20 ^M,
which is in reasonable agreement with the results of direct
binding studies (Fig. 3 A).
The existence of a high-affinity antagonist of eserine (anti-
body FKl) permits assessment of the pharmacology of
eserine-induced ion fiux on the level of the binding reaction
[28]. In agreement with the findings reported above, only
eserine and benzoquinonium but not acetylcholine, tubo-
curarine or decamethonium inhibited, at the concentrations
applied, binding of FKl to Torpedo membrane fragments.
Taken together, our binding studies yielded the following
findings, (a) The existence of eserine-competitive antibodies
suggests that the channel-activating binding site(s) for eserine
is located at the surface, not inside the channel of the nAChR.
(b) The eserine binding site is probably adjacent to the
acetylcholine site because benzoquinonium competes in bind-
ing with both ligands (thereby inhibiting channel activation).
(c) Blockade of the acetylcholine-activated channel [8-13]
is probably exerted from other site(s) than direct channel
activation by eserine because of the very different affinity
range of these sites.
DISCUSSION
Our data extend previous electrophysiological and bio-
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Fig. 3. Binding of eserine to membrane-bound nAChR from T.
marmorata. (A) Binding of ['HJeserine to Torpedo membrane frag-
ments. Torpedo membrane fragments (approx. 500 nM acetylcholine
binding sites) in 100 mM NaCI, 4 mM CaClj, 2 mM MgCli, 10 mM
Pipes pH 6.8, supplemented with 0.4 mg/ml bovine serum albumin
and 0.1 mM Tetram, were incubated, in the dark and at room tempera-
ture, for 30 min with different concentrations of [•'HJeserine (2 —
170 nM). After centrifugation of the reaction mixture, the concen-
tration of free eserine was determined from the radioactivity of an
aliquot of the supernatant, the concentration of bound eserine from
the radioactivity of the pellet. Nonspecific binding was determined in
the presence of 20 mM nonradioactive eserine. The data are plotted
in terms of the concentration of bound (Cb) versus free (cf) eserine.
They were fitted by assuming a single class of binding sites, a concen-
tration of sites of 500 nM, and a Kj value of 70 nM. (B) Binding of
['H]acetylcholine to membrane-bound nAChR in the presence and
absence of fixed concentrations of eserine. Under the same experimen-
tal conditions as described above. Torpedo membrane fragments
(approx. 1(K) nM acetylcholine binding sites) were incubated at room
temperature for 30 min with different concentrations of [•'Hjacetyl-
choline (0.02-1 nM) in the presence of no (O), 2 mM (A), 6 mM
( x ) and 10 mM ( n ) eserine, respectively. After separation by
centrifugation of solute and particulate phase, the radioactivity in the
supernatant and in the pellet were determined. Data are presented in
a double-reciprocal plot of the concentration of bound acetylcholine
(cb) versus free (c't) acetylcholine. From a secondary plot of the appar-
ent Ki values for acetylcholine binding versus the concentration of
eserine (additional experiments included), a Ki value of 3.9 mM was
obtained (linear regression, correlation coefficient r^ = 0.996)
nAChR-rich Torpedo marmorata membrane vesicles (Figs 1
and 2) are in qualitative and quantitative agreement with
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vious electrophysiological studies on nAChR from other
species [8 — 13] suggesting that our fmdings may not be limited
to only Torpedo receptor. As the major novel observation,
eserine is capable of activating the Torpedo nAChR channel,
and this activation is not antagonized by most antagonists of
acetylcholine (including D-tubocurarine and a-bungarotoxin)
but is antagonized by the monoclonal antibody FKl and by
benzoquinonium. Further supported by our binding studies,
we established in this way a new class of channel-activating
site(s) at the Torpedo nAChR that is clearly distinct in location
and pharmacology from the cholinergic sites. Epitope map-
ping studies employing synthetic peptides [25, 36] and affinity
labeling studies are presently under way in order to locate
conclusively in the primary structure of the nAChR the site
from which eserine exerts its ion-flux-stimulating activity. In
addition to these sites, separate sites exist (probably the local
anaesthetic binding sites previously identified [37, 38]) from
which eserine, at high concentrations, acts as a direct blocker
of the acetylcholine-activated channel [12].
Working with the nAChR from the mollusc Aplysia,
Carpenter et al. [39] have observed that eserine blocks binding
of a-bungarotoxin with an inhibition constant of 3 nM. By
intracellular recording from Aplysia neurons, the same
authors reported that eserine (100 nM) 'inhibits' the block by
a-bungarotoxin of acetylcholine channel activation. The latter
finding may have been caused by the direct channel activating
effect of eserine described here, while the first suggests that,
at the Aplysia nAChR, the binding sites for a-bungarotoxin
and eserine may partially overlap.
At the nAChR from Torpedo nobiliana electric organ, high-
afiinity binding sites for eserine {K^ « 20 - 50 ^M) have been
found which apparently overlap not only with those for a-
bungarotoxin but also with those for acetylcholine. In this
system eserine and a-bungarotoxin compete for nAChR bind-
ing, and eserine acts as a cholinergic antagonist [40].
At the neuromuscular junction of mammals, a-bungaro-
toxin and other antagonists of acetylcholine are known to
block neuromuscular transmission completely. Variations in
the pharmacology of nicotinic receptors from different species,
organs and brain regions are well documented [2,41]. In view
of the inherent limits of our in vitro assay, the possibility also
exists that eserine and acetylcholine bind to the same general
binding pocket at the Torpedo nAChR but that binding occurs
via different attachment points [25, 26].
Focussing again on the key findings of this study, (-)-
physostigmine, in the true sense, is not an agonist of
acetylcholine at T. marmorata nAChR but rather represents
a new class of its own of channel-activating ligands of the
receptor. Accordingly, this class of sites has its own agonists
(eserine) and antagonists (FKl, benzoquinonium). This raises
the question as to whether the channel-activating binding
sites for eserine serve a physiological function controlled by a
natural (endogenous) ligand. In other words, the nAChR, in
addition to serving as receptor for acetylcholine, might be the
receptor for yet another messenger molecule. Several com-
pounds known to affect nAChR function and development
may be considered as candidate messengers in this context
[42-45]. A similar multiplicity of receptive functions is not
unknown for neuroreceptors serving as ligand-gated cation
channels [46-49].
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